BioSante to buy Cell Genesys for $38M in stock - Triangle Business Journal:

vorotintseyqah.blogspot.com
BioSante (NASDAQ: BPAX) will pay 0.1615 of its own common sharesd for each share of CellGenesys CEGE). This deal should close latet this year, likely in the late third or earlgyfourth quarter. In the first quarter, Cell Genesys lost $8.7 or 10 cents a narrowed from a loss in the same period last yearof $22.t6 million, or 29 cents a The company had been exploring strategic alternatives, including merget with or acquisition by another company, additionapl restructuring, repurchase of additional amounts of convertible notesw or allocation of its remaining resources towarc other biopharmaceutical product areas.
Cell Genesysx had hired to help it figure out a The company already cut about 95 percent of its from 290 personsto 16, by eliminatintg all research and development, manufacturing, clinical and regulatoru activities. BioSante, based in Lincolnshire, Ill., focuses on drugs for sexual